Is CagriSema the same as cagrilintide or semaglutide?
No. CagriSema is a fixed mix of two drugs in one weekly shot: cagrilintide, a long-acting drug that switches on the amylin receptor, plus semaglutide, a GLP-1 drug. Together, REDEFINE 1 found 20.4% weight loss at 68 weeks versus 3.0% on a dummy shot, in 3,417 adults. REDEFINE 2 found 13.7% versus 3.4% in 1,206 people with type 2 diabetes. On its own, semaglutide as Wegovy 2.4 milligrams gave 14.9% at 68 weeks in STEP 1. On its own, cagrilintide gave 6.0% to 10.8% at 26 weeks in 706 people, versus 3.0% on a dummy shot. CagriSema is still experimental. An FDA application was filed in December 2025, and that is not an approval.
Studies in people from the compound pages this answer belongs to
- Cagrilintide
- Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial 2023 PMID 37364590
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial 2021 PMID 34798060
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) 2025 PMID 40544432
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of names, absences, and legal limits. Brand versus molecule, side effects this site's citations did not measure, how long the trials actually ran, what national legal-status fields can say, and why two-compound answers do not scale to a larger stack.